Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3IEHP)

• Drug Name: NN8555 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Phase 2	[1]
Rheumatoid arthritis	FA20	Discontinued in Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DM3IEHP

Molecule-Related Drug Atlas

Drug(s) Targeting NKG2 D activating NK receptor (KLRK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NKR-2 CAR-T Cells	DMDLJM1	Acute myeloid leukaemia	2A60	Phase 1	[3]
CYAD-101	DMSM42V	Colorectal cancer	2B91.Z	Phase 1	[4]
CM-CS1 T-cell	DMY5V4U	Acute myeloid leukaemia	2A60	Phase 1	[5]
NKR-2 cells	DMR5ATX	Acute myeloid leukaemia	2A60	Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NKG2 D activating NK receptor (KLRK1)	TTLRN4A	NKG2D_HUMAN	Antagonist	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030434)
• [3] ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
• [4] ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
• [5] ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
• [6] ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases